Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer

57Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

To test the hypothesis that plasminogen activator inhibitor-1 (PAI-1) may serve as a candidate marker for the malignancy of colorectal cancer (CRC), we performed a quantitative RT-PCR for PAI-1 gene and evaluated the possible relationship between PAI-1 gene expression levels and clinicopathological findings in CRC. A significant increase in PAI-1 expression scores was observed in lymph node metastasis-positive CRCs (2.19±ompared to negative ones (0.35±0.42) (P = 0.037) as well as in distant metastasis-positive CRCs (3.50±1.18) compared to negative ones (0.99±0.30). The PAI-1 expression score markedly increased with the tumour stage (P = 0.0063; ANOVA test). Moreover, multivariate analysis revealed the PAI-1 expression score to be a strong and independent prognostic factor for CRC (P = 0.0432). These results suggested that PAI-1 might serve as a new parameter for the prediction of prognoses in CRC. © 2005 Cancer Research.

Cite

CITATION STYLE

APA

Sakakibara, T., Hibi, K., Koike, M., Fujiwara, M., Kodera, Y., Ito, K., & Nakao, A. (2005). Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. British Journal of Cancer, 93(7), 799–803. https://doi.org/10.1038/sj.bjc.6602743

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free